Lipid management therapy widens past statins and PCSK9 monoclonals
Inclisiran maturity, bempedoic acid, lepodisiran and emerging oral PCSK9 programs, and ANGPTL3-targeted therapy are restructuring lipid management.
Lipid management has been a statin-and-injectable-PCSK9 category. Inclisiran (siRNA-targeted PCSK9 reduction with twice-yearly dosing) has commercial maturity, bempedoic acid provides an oral non-statin add-on, lepodisiran (an siRNA targeting Lp(a)) is in late-stage trials, oral PCSK9 inhibitor programs are reading out, and ANGPTL3-targeted programs widen the addressable lipid-target set. The category is more dynamic than at any point since the original statin era.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.